Chemotherapy News and Research

Latest Chemotherapy News and Research

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.

25 Apr 2011

New genetic discovery in Pulmonary Fibrosis

A new discovery in a deadly lung disease may change the direction of research while uncovering increased risk for many patients and families. The Coalition for Pulmonary Fibrosis and the Pulmonary Fibrosis Foundation applaud the efforts of scientists that led to the discovery of a genetic variation associated with the MUC5B gene which may increase the risk of developing Pulmonary Fibrosis.

25 Apr 2011

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.

25 Apr 2011

Saint Vincent Hospital to build new cancer center in downtown Worcester

Saint Vincent Hospital today announced it has signed a purchase and sale agreement with the CitySquare II Development Co. LLC , to build a medical office building that will house a new comprehensive cancer center in Worcester's CitySquare development. The new center, which represents a $21 million capital investment by Saint Vincent Hospital, is expected to open in January 2013.

22 Apr 2011

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

22 Apr 2011

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

Ahead of World Malaria Day (25 April), EU-funded researchers have discovered that drugs originally designed to inhibit the growth of cancer cells can also kill the parasite that causes malaria. They believe this discovery could open up a new strategy for combating this deadly disease, which, according to World Health Organisation statistics, infected around 225 million and killed nearly 800 000 people worldwide in 2009.

21 Apr 2011

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.

21 Apr 2011

Providing complete information about breast cancer treatment options often ends up overwhelming patients

Women who choose among different breast cancer treatment options make smarter choices when getting the information and making decisions in small doses rather than all at once, as is customary, a University of Michigan study found.

21 Apr 2011

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

A new discovery in a deadly lung disease may change the direction of research while uncovering increased risk for many patients and families. The Coalition for Pulmonary Fibrosis (CPF) and the Pulmonary Fibrosis Foundation (PFF) applaud the efforts of scientists that led to the discovery of a genetic variation associated with the MUC5B gene which may increase the risk of developing Pulmonary Fibrosis (PF).

21 Apr 2011

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.

21 Apr 2011

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

ACE inhibitors, commonly used to control high blood pressure and heart failure in women, may be associated with an increased risk of recurrence in women who have had breast cancer, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

21 Apr 2011

Cancer Centers of North Carolina buys WROS from Wake Radiology

Cancer Centers of North Carolina (CCNC), an affiliate of the United Network of US Oncology and the first practice to offer community-based outpatient cancer care in the Triangle with locations in Raleigh, North Raleigh, Cary, Dunn and Clayton, has purchased Wake Radiology Oncology Services (WROS) from Wake Radiology, the oldest and largest multi-site radiology group in central North Carolina.

21 Apr 2011

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute for Cancer Research demonstrated the ability of GM-CT-01 (DAVANAT®) to enhance the ability of tumor-specific T-lymphocytes to kill tumor cells.

20 Apr 2011

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.

20 Apr 2011

Minimizing neurological side effects in high-grade glioma patients may improve survival

Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.

20 Apr 2011

New findings show relation between breast implants and anaplastic large cell lymphoma

Breast implants appear to be associated with a rare form of lymphoma, but there is not yet evidence to show that the cancer is caused by implants or to suggest an underlying mechanism for how the disease might develop, according to a study by researchers from the RAND Corporation.

20 Apr 2011

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

20 Apr 2011

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Many of the newest weapons in the war on cancer come in the form of personalized therapies that can target specific changes in an individual's tumor. By disrupting molecular processes in tumor cells, these drugs can keep the tumor from growing and spreading. At the forefront of this work are Binghamton University researchers, Susan Bane, and Susannah Gal, who are deploying a new tool in their study of an enzyme called tubulin tyrosine ligase, or TTL.

20 Apr 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

Nausea and vomiting are most feared of all chemotherapy-related side effects

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

New genetic discovery in Pulmonary Fibrosis

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

Saint Vincent Hospital to build new cancer center in downtown Worcester

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

Providing complete information about breast cancer treatment options often ends up overwhelming patients

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

Cancer Centers of North Carolina buys WROS from Wake Radiology

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Minimizing neurological side effects in high-grade glioma patients may improve survival

New findings show relation between breast implants and anaplastic large cell lymphoma

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in